According to the company, the two patents (patent numbers are 8,771,732 and 8,765,175) will be Orange Book-listable.
The two patents complement two additional issued formulation patents, as well as an issued patent protecting the method of use of Nalbuphine ER in the ‘Methods for Treatment of Pruritus’, which expires in December 2032.
The company continues to prosecute additional claims to further improve its existing patent estate protecting Nalbuphine ER in itch.
Trevi president and chief executive officer Jennifer Good said the company is happy with the issued patent estate to date and will continue to pursue opportunities to protect Nalbuphine ER.
"Nalbuphine’s novel mechanism of action aligns well with multiple itch conditions, and we have initiated a pivotal trial in uremic pruritus and will be initiating a pivotal trial in prurigo nodularis later this year," Good said.